OverviewSuggest Edit
Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.
| Type | Public | |
| Founded | 1997 | |
| HQ | Salt Lake City, US | Map |
| Website | lipocine.com |
Recent NewsAll News
- Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
- Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™
- Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference
- Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018
Key People/Management at Lipocine
Mahesh V. Patel
Chairman, President and Chief Executive Officer
Morgan Brown
Executive Vice President and Chief Financial Officer
Greg Bass
Executive Vice President and Chief Commercial Officer
Jyrki Mattila
Executive Vice President and Chief Business Officer
Anthony DelConte
Chief Medical Director
Lipocine Office Locations
Lipocine has offices in Salt Lake City and Trenton
Salt Lake City, US (HQ)
675 Arapeen Dr #202
Trenton, US
3150 Brunswick Pike #130
Lipocine Financials and Metrics
Lipocine Revenue
Lipocine's revenue was reported to be $428.03 k in FY, 2018
| USD | |
|---|---|
Revenue (FY, 2018) | 428.0k |
Net income (FY, 2018) | (11.7m) |
EBIT (FY, 2018) | (11.3m) |
Market capitalization (10-Jun-2019) | 32.1m |
Closing stock price (10-Jun-2019) | 1.5 |
Cash (31-Dec-2018) | 8.1m |
Lipocine's current market capitalization is $32.1 m.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 428.0k | 428.0k | |||||||||||||
General and administrative expense | 1.2m | 1.9m | 1.0m | 871.8k | 1.1m | 1.1m | 1.7m | 4.4m | 3.2m | 1.4m | 1.8m | 2.0m | 1.7m | 1.7m | |
R&D expense | 1.6m | 3.4m | 6.0m | 3.2m | 1.9m | 3.2m | 4.7m | 2.7m | 2.6m | 1.5m | 3.1m | 4.1m | 1.4m | 1.5m | |
Operating expense total | 2.8m | 5.3m | 7.0m | 4.1m | 3.0m | 4.3m | 6.4m | 7.1m | 5.8m | 3.3m | 4.9m | 6.1m | 4.8m | 3.1m | 3.2m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 36.8m | 41.8m | 34.2m | 31.7m | 24.8m | 38.3m | 23.9m | 14.1m | 12.4m | 4.7m | 6.9m | 16.6m | 9.3m | 8.6m | 1.6m |
Current Assets | 37.1m | 42.0m | 35.4m | 32.0m | 25.0m | 44.1m | 42.3m | 38.6m | 33.2m | 29.4m | 27.1m | 27.9m | 26.1m | 31.6m | 25.3m |
Total Assets | 37.2m | 42.1m | 35.5m | 32.0m | 25.1m | 53.8m | 48.4m | 38.8m | 33.3m | 29.6m | 27.2m | 28.0m | 26.3m | 31.7m | 25.3m |
Accounts Payable | 1.5m | 773.0k | 641.8k | 399.1k | 379.5k | 398.8k | 456.8k | 1.1m | 989.0k | 865.0k | 853.5k | 1.1m | 803.8k | 388.4k | 406.5k |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (6.2m) | (5.3m) | (12.2m) | (16.3m) | (3.0m) | (7.2m) | (13.6m) | (7.0m) | (12.8m) | (3.2m) | (4.9m) | (11.0m) | (4.7m) | (2.7m) | (6.0m) |
Depreciation and Amortization | 15.7k | 3.0k | 6.1k | 9.4k | 8.7k | 19.6k | 6.7k | 15.5k | 7.1k | 14.2k | 5.3k | 9.7k | |||
Accounts Payable | 1.1m | (254.0k) | (385.2k) | (627.9k) | 379.5k | 30.1k | 150.6k | 570.1k | 482.0k | 865.0k | 607.6k | 867.9k | 803.8k | (209.7k) | (191.5k) |
Purchases of PP&E | (1.2k) | (1.9k) | (1.9k) | (21.3k) | (14.8k) | (28.7k) | (39.2k) | (59.6k) |
| USD | Y, 2018 |
|---|---|
Revenue/Employee | 42.8k |
Financial Leverage | 2.2 x |
Lipocine Online and Social Media Presence
Lipocine's Trends
Lipocine News and Updates
April 03, 2019
Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
SALT LAKE CITY, April 3, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court...
December 31, 2018
Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™
SALT LAKE CITY, Dec. 31, 2018 /PRNewswire/ -- Lipocine, Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically meaningful ex vivo conversion of testosterone...
December 21, 2018
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference
SALT LAKE CITY, Dec. 21, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the 2019 NASH-TAG Conference. The presentation will highlight data from multiple clinical...
November 07, 2018
Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018
SALT LAKE CITY, Nov. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018. Third Quarter and Recent Corporate Highlights Completed enrollment of 138 subjects in...
September 25, 2018
Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference
SALT LAKE CITY, Sept. 25, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, being held October...
August 07, 2018
Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018
SALT LAKE CITY, Aug. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018. Second Quarter and Recent Corporate Highlights Received a Complete Response Letter ("CRL")...
Lipocine Blogs
Lipocine Frequently Asked Questions
When was Lipocine founded?
Lipocine was founded in 1997.
Who are Lipocine key executives?
Lipocine's key executives are Mahesh V. Patel, Morgan Brown and Greg Bass.
How many employees does Lipocine have?
Lipocine has 10 employees.
What is Lipocine revenue?
Latest Lipocine annual revenue is $428 k.
What is Lipocine revenue per employee?
Latest Lipocine revenue per employee is $42.8 k.
Who are Lipocine competitors?
Competitors of Lipocine include Kither Biotech, CANbridge Life Sciences and Cognition Therapeutics.
Where is Lipocine headquarters?
Lipocine headquarters is located at 675 Arapeen Dr #202, Salt Lake City.
Where are Lipocine offices?
Lipocine has offices in Salt Lake City and Trenton.
How many offices does Lipocine have?
Lipocine has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies